FDA Approves Class II Status for Rare Receptor Test System
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting the anti-phospholipase A2 receptor test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this important medical tool faster. Labs and device makers should get ready for these new rules, which aim to make things smoother without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Test Classified as Class II
If you are a patient, the FDA has classified the anti-phospholipase A2 receptor immunological test system as Class II (special controls). The FDA says this classification provides a reasonable assurance of the test's safety and effectiveness and may enhance patients' access by reducing regulatory burdens.
Labs and Makers Must Prepare
If you operate a laboratory or make this test, the FDA says you should prepare for new Class II special controls for the anti-phospholipase A2 receptor immunological test system. The agency states the change aims to reduce regulatory burdens and make processes smoother without extra costs or delays.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in